Sunitinib (Sutent) for Mesothelioma

Brand named Sutent, Sunitinib is a receptor tyrosine kinase inhibitor (RTKI) used to treat renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). It is also in clinical trials for mesothelioma treatment. The drug was approved on January 26th of 2006, and is the first cancer fighting drug to be approved for two different indications at the same time. This medication is widely prescribed by doctors and has become the de facto treatment for RCC and GIST. Sunitinib operates by inhibiting the signaling in cells including platelet-derived growth factor receptors and vascular endothelial growth factor receptors which cause tumor formation and growth. The effect is that the growth of tumors is slowed and the cancerous cells die.

Sutent is administered orally, and the common dosage cycle is once daily for a period of four weeks with a two week break between cycles. A dietary requirement while taking Sutent is to avoid eating grapefruit or drinking grapefruit juice as it will cause adverse reactions. While most patients experience few or manageable side effects, less than ten percent of patients have had heart failure. Some of the drug's other side effects include:

Weakness
Diarrhea
Vomiting
Bloating
Weight loss
Depression
Tingling in the extremities
Rashes

If any of the following side effects are experienced, you should contact your doctor immediately:

Shortness of breath
Sudden pain or swelling in the extremities
Increased heart rate or irregular heart rate
Sudden chest or back pains
Rapid weight gain
Black, pink, or bloody mucus when coughing
Excessive urination
Unexpected blood loss

Abstract: Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).

To receive a FREE Mesothelioma Web information packet** or to make a request, please fill out the following form :

**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

Resources

This site complies with the HONcode standard for trustworthy health information: verify here